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6 5 0  T. FOTSIS ET AL 
The consumption of a plant-based diet can prevent the development and progression of 
chronic diseases associated with extensive neovascularization, including the progression 
and growth of solid malignant tumours. We have previously shown that the plant-derived 
isoflavonoid genistein is a potent inhibitor of cell proliferation and in vitro angiogenesis. 
Moreover, the concentration of genistein in the urine of subjects consuming a plant-based 
diet is 30-fold higher than that in subjects consuming a traditional Western diet. We have 
also reported that certain structurally related flavonoids are more potent inhibitors than 
genistein. Indeed, 3-hydroxyflavone, 3',4'-dihydroxyflavone, 2',3'-dihydroxyflavone, 
fisetin, apigenin and luteolin inhibit the proliferation of normal and tumour cells as well as 
in vitro angiogenesis at half-maximal concentrations in the lower micromolar range. The 
wide distribution of isoflavonoids and flavonoids in the plant kingdom, together with their 
anti-angiogenic and anti-mitotic properties, suggest that these phytoestrogens may 
contribute to the preventive effect of a plant-based diet on chronic diseases, including solid 
tumours. 
Key words: isoflavonoids; genistein; flavonoids; diet; inhibition; angiogenesis; pro- 
liferation. 
ANGIOGENESIS  
Angiogenesis, the generation of new capillaries from pre-existing vessels, is 
virtually absent in the healthy adult organism, in which it is restricted to a 
few conditions including wound healing and the formation of corpus 
luteum, endometrium and placenta. These conditions of physiological 
angiogenesis represent ordered, tightly regulated and self-limited processes 
(Klagsbrun and Folkman, 1990). However, in certain pathological 
conditions, angiogenesis is dramatically enhanced and loses its self-limiting 
capacity (Denekamp, 1990). Although pathological angiogenesis is seen 
during the development and progression of many diseases, such as 
rheumatoid arthritis, psoriasis and diabetic retinopathy, from a clinical 
perspective the most important manifestation of pathological angiogenesis is 
probably that induced by solid tumours (Folkman, 1985). Well-vascularized 
tumours expand both locally and by metastasis, while avascular tumours do 
not grow beyond a diameter of 1 - 2 r a m  (Folkman and Cotran, 1976; 
Klagsbrun and Folkman, 1990). 
Although the mechanisms responsible for persistent angiogenesis are 
still unclear and certainly not the same in each disease, recent evidence 
indicates that they all lead to an imbalance between angiogenic factors 
and inhibitors (Liotta et al, 1991; Hanahan and Folkman, 1996). 
Recognition of the importance of angiogenesis has led to the search of 
angiogenesis inhibitors, which, by tilting the balance towards inhibition, 
can stop the process of persistent, unregulated pathological neovascular- 
ization (Crum et al, 1985; Ingber et al, 1990). Such compounds may find 
important applications in the treatment of angiogenic diseases, including 
cancer. 
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DIETARY INGESTED COMPOUNDS INHIBIT ENDOTHELIAL 
CELL PROLIFERATION 
Dietary factors contribute to about one-third of potentially preventable 
cancers (Adlercreutz, 1990), and the long-known preventive effect of plant- 
based diets on tumourigenesis and other chronic diseases is well docu- 
mented (Miller, 1990). Breast cancer, prostate cancer and endometrial 
cancer belong to the group of hormone-dependent cancers that, in addition 
to colon cancer and coronary heart disease, are among those chronic 
diseases which have a lower incidence in Asia than in Western countries 
(Rose et al, 1986). Migrants from Asia who maintain their traditional diet 
do not increase their risk of these diseases (Kolonel, 1988); however, an 
increased risk of these diseases accompanies a change towards a 
Westernized diet (Lee et al, 1991). These data indicate that certain plant- 
derived dietary groups might contain compounds exerting anti-mitotic and 
anti-tumourigenic effects, thereby offering anti-cancer protection to 
individuals consuming such diets. The identification and characterization of 
such compounds might provide us with additional chemotherapeutic agents 
for pharmacological intervention in cancer. 
That dietary ingested compounds could be modulating the proliferation 
of tumour cells and pathological angiogenesis appeared to us an important 
possibility meriting further investigation. If dietary compounds were to 
inhibit angiogenesis, this could explain, at least in part, the long-known 
preventive effect of plant-based diets on tumourigenesis and other chronic 
diseases, such as inflammation (Adlercreutz, 1990). We have, therefore, 
examined this possibility by screening the urine of human subjects 
consuming a diet rich in plant products for the presence of anti-mitotic and 
anti-angiogenic compounds (Fotsis et al, 1993, 1995). Towards this 
purpose, we have used a purification procedure (Figure 1A) previously 
developed by us to separate lipophilic compounds of steroid- or steroid-like 
structure (Fotsis, 1987; Fotsis and Adlercreutz, 1987; Adlercreutz et al, 
1991a). Figure 1B outlines the various fractions (1-6) obtained from the 
purification of urine and their effect on basic fibroblast growth factor 
(bFGF)-stimulated proliferation of bovine brain-derived capillary endo- 
thelial cells (BBCE). Fractions 1, 2 and 4 were able to inhibit the pro- 
liferation of endothelial and neuroblastoma cells. Fraction 4 was not further 
examined as it contains neutral steroids (Fotsis and Adlercreutz, 1987), 
which are known angiogenesis inhibitors (Crum et al, 1985). 
THE ISOFLAVONOID GENISTEIN INHIBITS THE IN VITRO 
PROLIFERATION OF ENDOTHELIAL CELLS 
Fraction 1, which exhibited strong inhibition of the in vitro proliferation of 
endothelial cells, contained diphenolic compounds (Figure 1). Using gas 
chromatography-mass spectroscopy (GC-MS), initial identification was 
carried out by comparing the mass spectra of the different peaks with those 
of reference mass spectra collections. Synthetic standards of potential 
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Figure 1. Fractionation of human urine and the effect of various semipure urine preparations on the 
proliferation of vascular endothelial cells. (A) Urine was fractionated as described (Fotsis, 1987; 
Fotsis and Adlercreutz, 1987; Adlercreutz et al, 1991a). The flow diagram shows the chromatographic 
steps, the fractions obtained (numbered 1 to 6) and the compound classes contained in each fraction. 
(B) Bovine brain-derived capillary endothelial cells were seeded at a density of 5000 cells/ml into 
each well and, every other day, received 10btl aliquots containing bFGF (2.5 ng) plus 10 gl aliquots 
(containing an equivalent of 3.2 ml native urine) of th e purified urine fractions (fractions 1-6  of 
Figure 1A) diluted in buffer or buffer only. The cells were counted after 5 days. Values are expressed 
as a percentage of the controls value, i.e. cells receiving bFGF and buffer only (approximately 
100 000 cells per well). Figure 1A reproduced from Fotsis et al (1993), with the permission of the 
National Academy of Sciences, USA. Figure 1B reproduced from Fotsis et al (1995), with the 
permission of the American Society for Nutritional Sciences. 
candidate compounds were then prepared, and definite identification was 
established by comparing their mass spectra with those of the unknown 
compounds. In this way, we were able to demonstrate the presence of the 
isoflavonoids genistein, daidzein and O-desmethylangolensin in fraction 1 
and the lignans enterodiol, enterolactone and matairesinol as well as the 
isoflavonoid equol in fraction 3 (Adlercreutz et al, 1991b). Most 
isoflavonoids have weak oestrogenic activity. Indeed, high levels of circu- 
lating equol have been shown to be responsible for the infertility observed in 
Australian sheep grazing on a certain type of subterranean clover rich in 
isoflavonoids (Shutt, 1976). In this syndrome, known as clover disease of 
sheep, ewes exhibited cystic degeneration of the ovaries and insensitivity of 
the hypothalami to oestradiol (Shutt, 1976). 
The synthetic analogues of the identified compounds were then tested with 
regard to their effect on the bFGF-stimulated proliferation of BBCE cells. 
Genistein had a potent and dose-dependent inhibitory effect on BBCE cell 
proliferation, with half-maximal and maximal effects at 5 and 50 btM concen- 
trations respectively (Fotsis et al, 1993). In contrast, the remaining iso- 
flavonoids, some of which are closely related to genistein, were considerably 
(5-20 times) less potent. Genistein also inhibited the proliferation of vascular 
endothelial cells derived from bovine adrenal cortex (ACE) or aorta (BAE). 
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GENISTEIN TARGETS PROLIFERATING BUT NOT 
QUIESCENT CELLS 
Endothelial cells were not the only target of genistein. The proliferation of 
low-density cultures of various normal (NIH-3T3 mouse embryonic fibro- 
blasts) and tumour (SH-EP and Kelly human neuroblastoma, SK-ES1 
Ewing's sarcoma, RD and A-204 human rhabdomyosarcoma, and Y-79 
human retinoblastoma) cells was also inhibited by genistein, with half- 
maximal concentrations varying between 10 and 45 ~M (Schweigerer et al, 
1992). Although endothelial cells are slightly more sensitive (ICs0 = 6 ~tM) 
to the inhibitory effect of genistein, it appears that genistein has a broad 
inhibitory effect on proliferating cells. 
In low-density cultures of proliferating endothelial cells, genistein 
induced marked morphological changes: at concentrations up to 25 p.M, 
genistein induced a highly spread morphology compatible with growth 
arrest; cell densities always exceeded those determined at seeding (Fotsis et 
al, 1993), indicating that cell death was not involved. When exposed to 
genistein concentrations above 25 ~tM, the cells acquired an elongated 
morphology and eventually died. These results indicate that genistein is 
cytostatic up to concentrations of approximately 25 ~tM and that it becomes 
cytotoxic above this level. Reversibility experiments, in which low-density 
cultures of endothelial cells were exposed to bFGF (2.5 ng/ml) and increas- 
ing concentrations of genistein, and then to medium without genistein, 
confirmed this assumption (Figures 2 and 3A). The result was the same on 
uncoated and gelatin-coated substrata. In contrast, confluent, quiescent 
endothelial cells did not exhibit toxicity signs even at genistein concentra- 
tions up to 100 ~tM (Figure 3B). These data clearly suggest that genistein 
targets only proliferating cells, leaving quiescent, non-dividing cells un- 
affected. This property is important with respect to the possible use of this 
compound therapeutically as fewer side-effects are likely to be expected. 
GENISTEIN INHIBITS ANGIOGENESIS IN VITRO 
Having established the inhibitory effects of genistein on the proliferation of 
endothelial cells, it was interesting to investigate whether genistein had 
additional effects on other functions of endothelial cells important for angio- 
genesis. Angiogenesis is a complex process requiring the co-ordinated, 
sequential involvement of a number of cellular events in addition to 
proliferation. Indeed, the formation of new capillaries begins with a local- 
ized breakdown of the basement membrane of the parent vessel through the 
finely tuned elaboration of proteolytic enzymes and their inhibitors (Pepper 
and Montesano, 1990), followed by the migration of endothelial cells and 
invasion of the surrounding matrix. The initial sprout elongates further as a 
result of continued migration and endothelial cell replication. Once a lumen 
has been formed, the capillary fuses with the tip of another maturing sprout, 
forming a functional capillary loop (Folkman and Klagsbrun, 1987). 
Proteolytic degradation of the extracellular matrix by endothelial cells is 
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Figure 2. Time course and reversibility of the effect of genistein on the proliferation of vascular 
endothelial cells. Bovine brain-derived capillary endothelial cells were seeded at a density of 5000 
cells per well and received either no additions (A, O) or every other day bFGF (2.5 ng/ml) without 
([]) or with 1 (A), 10 (11) or 100 (0)  gM concentrations of genistein. On day 5 (indicated by the 
arrow), the cells were washed and received medium free of genistein containing buffer (O) or bFGF 
(2.5 ng/ml) (A, D, A, III, O) only. Duplicate wells were counted at the indicated times. The horizontal 
line indicates the cell seeding density. Reproduced from Fotsis et al (1995) with the permission of the 
American Society for Nutritional Sciences. 
controlled by angiogenic factors, for example bFGF, which induce the 
production of urokinase-type plasminogen activator (Montesano et al, 1986) 
and its physiological inhibitor, plasminogen activator inhibitor-1 (Pepper 
and Montesano, 1990). Genistein markedly reduced both bFGF-stimulated 
and basal levels of both plasminogen activator and plasminogen activator 
inhibitor-1 activity in bovine microvascular endothelial cells (BME) (Fotsis 
et al, 1993). Moreover, genistein inhibited the bFGF-induced migration of 
endothelial cells in wounded confluent monolayers of endothelial cells (data 
not shown). Inhibition of the production of proteolytic enzymes and the 
migration of endothelial cells by genistein thus represents a more complex 
interference by the compound, with important early events of angiogenesis 
in addition to endothelial cell proliferation. 
The combined effects of genistein on the proliferation, proteolytic 
enzyme production and migration of endothelial cells prompted us to 
investigate the effects of the compound on an experimental in vitro system 
that mimics angiogenesis in vivo. As previously shown (Montesano et al, 
1986), BME cells seeded on the surface of collagen gels (Figure 4A) invade 
the gels when exposed to bFGF and form capillary-like tubes beneath the 
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gel surface (Figure 4B). Genistein alone at concentration of 200 pM had no 
effect on confluent BME cultures (Figure 4C). However, when added 
together with bFGF, it inhibited their ability to invade the gels and generate 
capillary-like structures (Figure 4D). A quantitative analysis revealed that 
genistein inhibited the bFGF-induced invasion of BME cells, with a half- 
maximal effect at a concentration of approximately 10 btM (Fotsis et al, 
1993, 1997). 
Figure 4. The effect of genistein on in vitro angiogenesis. Three-dimensional collagen gels were 
prepared in 18 mm tissue culture wells as described (Montesano and Orci, 1985). 5 x 104 bovine 
microvascular endothelial (BME) cells (in a volume of 0.5 ml) were seeded into each well, and the 
medium was changed every 2 - 3  days until the cells were confluent. After confluence, they received 
either no additions (A), bFGF (30 ng/ml) only (B), genistein (200 pM) only (C) or genistein (200 pM) 
2 hours prior to bFGF (30 ng/ml) (D). After 2 days of incubation, the medium was changed and the 
cells exposed to the same conditions again. Representative pictures were taken after another 3 days. 
In (B), the arrow shows the lumen of a capillary-like tube, and in (D), genistein inhibits the formation 
of such tubes. Bar = 150 p.M. Quantification was carried out by measuring the total additive length of 
all the cells that penetrated the underlying gel either as single cells or in the form of cell cords. The 
addition of genistein 2 hours prior to the addition of bFGF significantly (* P <0.025; ** P <0.0001) 
inhibited bFGF-induced invasion. Reproduced from Fotsis et al (1993) with the permission of the 
National Academy of Sciences, USA. 
SEVERAL OTHER MEMBERS OF THE FLAVONOID 
FAMILY INHIBIT ENDOTHELIAL AND TUMOUR 
CELL PROLIFERATION 
The promising results with the isoflavonoid genistein prompted us to 
extend these studies by investigating the anti-mitotic and anti-angiogenic 
effects of other members of the large flavonoid family. Many fiavonoids 
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bind to the oestrogen receptor and possess oestrogenic activity (Miksicek, 
1994, 1995). Flavonoid aglycones all consist of a benzene ring (A) fused 
with a six-member ring (C), which in the 2-position carries a phenyl ring 
(B) as a substituent (Table 1), whereas isoflavonoids carry the B ring in 
position 3. Flavonoids are widely distributed in the plant kingdom 
(Harborne, 1973; Harborne and Marby, 1982; Middleton, 1988), rendering 
them very attractive targets for further studies. Most of them possess vicinal 
hydroxyls in one of the phenyl rings, being therefore eluted in fraction 2 of 
the purification method (see Figure 1A above). Indeed, fraction 2 exhibited 
strong inhibitory activity on the proliferation of endothelial cells in vitro 
(see Figure 1B above), providing further support for the investigation of the 
anti-mitotic and anti-angiogenic properties of flavonoids. 
Towards this purpose, a series of flavonoid metabolites were tested with 
regard to their effect on the bFGF-stimulated proliferation of BBCE cells. 
Table 1. Substances tested. The chemical structures of the various substances tested in vitro for their 
anti-proliferative and anti-carcinogenic activities 
Substitution 
Chemical formula Name 5 7 2" 3' 4' 5' 
Havones Flavone H H H H H H 
3" 5-Methoxyflavone OCH 3 H H H H H 
2'J'-.~4' Crysin OH OH H H H H 
8 I B I I  2', 3"-Dihydroxyflavone H H OH OH H H 
7 ~ /O  2 )..~_ ~5' 3', 4'-Dihydroxyflavone H H H OH OH H 
" ~  Apigenin OH OH H H OH H 
6 Luteolin OH OH H OH OH H 
O Luteolin-7-glucoside OH OGLC H OH OH H 
Flavanones 
o 
Hesperetin OH OH H OH OCHs H 
Eriodictyol OH OH H OH OH H 
Havonols 
o 
3-Hydroxyflavone H OH H H H H 
Fisetin H OH H OH OH H 
Quercetin OH OH H OH OH H 
Myrisetin OH OH H OH OH OH 
Catechin Coumarin 
m v OH 
OH 
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The list of the flavonoids was selected to cover a large range of structures 
in order to facilitate potential structure-activity relationships (Table 1). To 
this list, coumarin was added as a control because of its closely related 
chemical structure. This initial experiment showed that several flavonoid 
metabolites could inhibit the in vitro proliferation of BBCE at half- 
maximal concentrations in the lower micromolar range (Table 2). To the 
best of our knowledge, there are no previous reports on the effects of  
flavonoids on endothelial cells, the target cells in angiogenesis. At least 
three flavonoids, 3', 4'-dihydroxyflavone, luteolin and 3-hydroxyflavone, 
inhibited the bFGF-induced proliferation of BBCE cells (Table 2 and 
Figure 5) at a lower half-maximal inhibitory concentration (1.4, 1.9, and 
2.7 btmol/1 respectively) than that of genistein (5 -6  btmol/1) (Fotsis et al, 
1993). There was no specificity towards any endothelial subtype, BAE, 
ACE and human umbilical vein endothelial (HUVE) all being inhibited by 
the most potent flavonoids in a manner similar to that of BBCE cells (data 
not shown). 
Next we investigated the anti-proliferative effects of flavonoids on 
various normal and tumour cells. The rationale was twofold: first, to 
investigate the possible direct anti-tumour effects of flavonoids, and 
second, to observe whether there is any selectivity in their anti-mitotic 
activity. Towards this end, several normal and tumour cells were employed, 
all of human origin. The normal cells included fibroblasts (HFK2) and 
Table 2. Anti-proliferative effects of flavonoids. The half-maximal concentration (gmol/1) of the 
inhibitory effect of the various substances tested on the in vitro proliferation of bovine capillary 
endothelial cells (BBCE), human fibroblasts (HFK2), human keratinocytes (HaCaT), breast cancer 
adenocarcinoma cells (MCF7) and human neuroblastoma cells (SHEP and WAC2).  
BBCE H F K 2  H a C a T  MCF7  SHEP W A C 2  
Flavones 
Flavone 8.5 
5-Methoxyf lavone 12.0 
3',4'-Dihydroxyflavone 1.4 9.5 1.5 0.7 5.0 
Chrysin 9.0 25.0  20.0 7.0 5.0 
Apigenin 6.5 10.0 6.0 3.5 4.0 
Luteolin 1.9 7.6 4.0 6.5 4.0 
Luteolin-7-glucoside 18.0 6.0 6.0 4.0 
Flavonoles 
3-Hydroxyf lavone  2.7 2.8 2.1 
Fisetin 8.6 . 20.1 20.0 10.6 7.0 
Quercetin 5.35 36.2 > 5 0 . 0  5.55 8.0 
Myricetin 28.0 40.0  40.0 n.e. 
Flavanones 
Eriodictyot 7.0 > 5 0 . 0  15.0 18.0 10.0 
Hesperetin 30.0 n.e. n.e. 40.0 > 50.0 
Flavan-3-ol 
Catechin >50 .0  > 5 0 . 0  n.e. n.e. n.e. 
Coumarins 






n.e. = no effect. 
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Figure 5. The effect of increasing concentrations of flavonoids on the proliferation of bovine capillary 
endothelial (BBCE) cells. BBCE cells were seeded at a density of 5000 cells per well and received 
bFGF (2.5 ng/ml) every other day. In addition, they received, every other day, 5 p.1 aliquots of solvent 
only or of solvent containing the indicated concentrations of 3',4'-dihydroxyflavone (O), luteolin (IlL 
3-hydroxyflavone (O), fisetin (A) or quercetin (D). The cells were counted after 5 days. The values are 
expressed as a percentage of that for controls, i.e. cells receiving solvent only. Reproduced from Fotsis 
et al (1997), with the permission of the American Association for Cancer Research. 
keratinocytes (HaCaT). The tumour cells were also of different tissue 
origins: MCF7 cells from breast adenocarcinoma, and SHEP and WAC2 
neuroblastoma ceils of neuroectodermal origin. WAC2 cells are stable 
transfectants of SHEP cells that express the MYCN oncogene and thus 
have an increased proliferative potential on the same genetic background as 
the SHEP cells (Schweigerer et al, 1990). 3', 4'-Dihydroxyflavone, luteolin, 
and 3-hydroxyflavone were again among the most potent anti-proliferative 
metabolites (Table 2). As for endothelial ceils, several of the flavonoids 
exhibited a potent anti-mitotic activity, especially on tumour cells, whereas 
others had minimal or no effect. Among the normal cell types, there 
appeared to be a greater inhibitory effect on endothelial cells than on 
fibroblasts and keratinocytes (Table 2), indicating a certain degree of 
selectivity towards endothelial cells. In contrast, the inhibitory effect of 
flavonoids on tumour cells was comparable to that of endothelial cells 
(Table 2). It is possible that the rapid proliferation of the latter in response 
to bFGF stimulation accounts for the similar inhibitory profiles seen with 
endothelial and tumour cells. These results point to a selective targeting of 
rapidly proliferating cells, a conclusion that is supported by the results 
obtained with the isoflavonoid genistein (Fotsis et al, 1995). 
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SELECTED FLAVONOIDS INHIBIT ANGIOGENESIS IN 
VITRO IN A MORE POTENT MANNER COMPARED 
TO GENISTEIN 
In order to examine the potential of flavonoids as inhibitors of angio- 
genesis, we tested selected flavonoids in the in vitro angiogenesis assay on 
three-dimensional collagen gels, described above for genistein. When 
10 ~tm concentrations of the most potent anti-mitotic flavonoids were added 
together with a synergistic combination of bFGF and VEGF (Pepper et al, 
1992), they inhibited the ability of BME cells to invade the gels and 
generate capillary-like structures. A quantitative analysis revealed that 
several flavonoids inhibited the bFGF/VEGF-induced invasion of BME 
cells to a greater extent than did the same concentration of genistein (Figure 
6). A more extensive evaluation, carried out in a dose-response manner, 
confirmed these findings and revealed a half-maximal concentration for the 
inhibition of in vitro angiogenesis that closely correlates with that of the 
anti-mitotic effects (data not shown). It is noteworthy that the order of 
potency of the various flavonoids with respect to anti-mitotic effects and 
the inhibition of in vitro angiogenesis did not strictly correlate. However, 
the requirement for a non-hydroxylated ring C with an oxo function at 
position 4 and a C2-C3 double bond is also valid for the inhibition of in 
vitro angiogenesis, as catechin is once again totally inactive. 
STRUCTURE-ACTIVITY RELATIONSHIP ISSUES 
Although anti-proliferative effects of flavonoids have been previously 
reported (Kandaswami et al, 1991; Huang et al, 1994; Yit and Das, 1994; 
Hirano et al, 1995), most of these studies were confined to the effects of 
single or a few metabolites on one or two cell types. This has made it 
difficult to draw any conclusion regarding a potential structure-activity 
correlation. Our studies allowed a more comprehensive approach by 
employing the testing of a set of various flavonoid structures on several 
normal and tumour cells of different origin. Our results clearly show that a 
non-hydroxylated ring C with an oxo function at position 4 and a C2-C3 
double bond is required for maximal biological activity. Catechin, which 
lacks both the C4 oxo group and the C2-C3 double bond, is completely 
devoid of anti-proliferative activity. Eriodictyol, the flavanone derived from 
reduction of the C2-C'3 double bond of the flavone luteolin, is at least three 
times weaker in inhibiting all the cells tested. The presence of a hydroxyl 
function in position 3, as occurs in flavonols, seems to modify the anti- 
mitotic activity in an unpredictable manner. Thus, 3-hydroxyflavone, the 3- 
hydroxylated flavonol derived from flavone, has an anti-proliferative activity 
which is fourfold greater. In contrast, quercetin, the flavonol derived from 
luteotin, is 2.5-fold weaker in its inhibition of cell proliferation. The catechol 
structure alone is insufficient for the inhibition of proliferation. This is 
clearly demonstrated by catechin, which, despite the presence of aromatic 
vicinal hydroxyls at positions 3' and 4', does not have an anti-mitotic effect. 
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Figure 6. The effect of flavonoids on in vitro angiogenesis. Bovine microvascular endothelial cells 
(BME) were grown to confluence on three-dimensional collagen gels as described (Montesano and 
Orci, 1985). After confluence, they received solvent or recombinant human bFGF (10 ng/ml) plus 
vascular endothelial growth factor (VEGF) (30 ng/ml) with or without 10 gmol/l concentrations of the 
substances to be tested. After 2 days of incubation, the medium was changed and the cells exposed to 
the same conditions again. Quantitative analysis was carried out on BME cells treated for 5 days as 
described above. Fields measuring I mm x 1.4 mm were then randomly selected and photographed, 
and the BME cell invasion was quantified by measuring the total length of all the cells that penetrated 
the underlying gel either as single cells or in the form of cell cords. The results are expressed as a per- 
centage of that for controls, i.e. cells receiving solvent and recombinant human bFGF plus VEGE 
DHF=dihydroxyflavone; HF=hydroxyflavone. Reproduced from Fotsis et al (1997), with the 
permission of the American Association for Cancer Research. 
Also, 3-hydroxyflavone, which has no catechol functions, has anti-prolifer- 
ative activity comparable to that of the catecholic metabolites luteolin and 3', 
4'-dihydroxyflavone. On the other hand, hesperetin, derived from 
methylation of the catechol hydroxyl at C-4' of eriodictyol, inhibits BBCE 
cells with a half-maximal concentration of 30 gmol/1, which is fourfold 
weaker than the anti-mitotic activity of the catecholic eriodictyol (7 gmol/1). 
Although several of the flavonoid metabolites tested exhibited stronger 
half-maximal inhibitory concentrations on endothelial cell proliferation 
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compared with the isoflavonoid genistein, this difference does not warrant 
the conclusion that ttavonoid metabolites are more potent than isomeric 
isoflavonoids. Indeed, apigenin, the corresponding flavonoid isomer of 
genistein with hydroxylations at positions 5, 7 and 4', exhibits a com- 
parable half-maximal inhibitory concentration (6.5 gmol/1). 
MECHANISM OF ACTION 
Flavonoids exhibit several interesting biochemical properties Havsteen, 
1983). The inhibition of tyrosine kinases (Graziani et al, 1983; Cunningham 
et al, 1992) and protein kinase C (PKC) (Ferriola et al, 1989) are, however, 
of particular importance with regard to cellular processes studied in our 
investigations. Flavonoids are competitive inhibitors with respect to the 
adenosine triphosphate (ATP) binding site (Graziani et al, 1983) on a variety 
of enzymes, a region of considerable homology between kinases. Indeed, 
genistein has been shown to be a competitive inhibitor of ATP binding to the 
catalytic domain of tyrosine kinases (Akiyama et al, 1987) and was found to 
inhibit epithelial growth factor (EGF) receptor (Akiyama et al, 1987) and 
platelet-derived growth factor (PDGF) receptor (Hill et al, 1990) tyrosine 
kinase activities both in intact cells and in vitro. This appears as an attractive 
hypothesis, since high-affinity fibroblast growth factor (FGF) receptors are 
tyrosine kinases (Ullrich and Schlesinger, 1990) and since vanadate, an 
inhibitor of phosphotyrosine phosphatases, induces angiogenesis in the 
collagen gel assay (Montesano et al, 1988). In this context, apigenin was 
found to inhibit both PKC and TPA-stimulation of the FGF receptor (Huang 
et al, 1996). 
A further important target of flavonoids appears to be 1-phospatidyl- 
inositol kinase (PI kinase) (Singhat et al, 1995), a key enzyme in signal 
transduction leading to the production of second messengers, inositol 1,4,5- 
trisphosphate (IP3) and diacyglycerol (DAG). Quercetin in breast 
carcinoma cells reduced the concentration of PI kinase and IP3 within 60 
minutes to 5% and 6% respectively (ICso: 6 gmol/1). However, no other 
flavonoids were tested in this study (Singhal et al, 1995). 
Synthetic analogues of flavonoids are potent inhibitors of cell-division- 
cycle 2 (cdc2) (Losiewicz et al, 1994) and cyclin-dependent (CDK) kinases 
(Carlson et al, 1996; De Azevedo et al, 1996), thereby inhibiting cell cycle 
progression. At least in the case of cdc2, the inhibition was competitive 
with respect to ATP binding (Losiewicz et al, 1994). Although the 
inhibition of kinases appears to be the most likely target, selected 
flavonoids have been reported to inhibit the DNA binding or the DNA re- 
ligation step of eukaryotic topoisomerase I (Boege et al, 1996). The strong 
scavenging of free radicals (Havsteen, 1983) does not appear to be the 
mechanism of anti-mitotic and anti-angiogenic activity of flavonoids. 
Indeed, myricetin and catechin, some of the strongest protectors against 
single-stranded breaks induced by singlet molecular oxygen (Devagagayam 
et al, 1995), are devoid of anti-mitotic or anti-angiogenic activity. 
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FUTURE PROSPECTS 
Flavonoids comprise a large group of naturally occuring, low-molecular 
weight substances that are present in fruits, vegetables, nuts, seeds, stems, 
leaves, flowers, bark and the roots of most plants as well as tea, coffee and 
wine (Harborne, 1973; Harborne and Marby, 1982; Middleton, 1988). The 
average Western-type diet is estimated to contain approximately 23 mg per 
day of quercetin, kaempferol, myricetin, apigenin and luteolin (Hertog et 
al, 1993), the total content of all naturally occurring flavonoids not being 
known. There is also a lack of information about the content of flavonoids 
in the diet of vegetarians. However, as the concentration of genistein in the 
urine of vegetarians is increased 30-fold compared with omnivores 
(Adlercreutz et al, 1991a, 1991b, 1995), it is possible that similar values 
might be also anticipated for flavonoids. The development of sensitive 
methods for the determination of flavonoids in biological materials, a task 
that our group has already undertaken, is expected to provide valuable 
information in this respect. Considering the biological functions of 
flavonoids presented in this and previous studies, it is quite possible that 
flavonoids might contribute to the preventive effects of a vegetarian diet on 
the incidence of and mortality from cancer. In this respect, animal experi- 
ments have already shown that flavonoids exert inhibitory effects on 
carcinogenicity (Elangovan et al, 1994; Das et al, 1995). Further studies 
should focus on the in vivo effects of flavonoids on angiogenesis and 
tumourigenesis models. 
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